{"id":3495,"date":"2026-07-21T15:36:44","date_gmt":"2026-07-21T19:36:44","guid":{"rendered":"https:\/\/aspenpharma.ca\/?p=3495"},"modified":"2026-07-21T15:41:26","modified_gmt":"2026-07-21T19:41:26","slug":"aspen-pharmacare-canada-receives-health-canada-approval-for-a-generic-equivalent-of-ozempic","status":"publish","type":"post","link":"https:\/\/aspenpharma.ca\/fr\/2026\/07\/21\/aspen-pharmacare-canada-receives-health-canada-approval-for-a-generic-equivalent-of-ozempic\/","title":{"rendered":"Aspen Pharmacare Canada receives Health Canada approval for a generic equivalent of Ozempic\u00ae"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong><em>New generic equivalent of Ozempic<sup>\u00ae<\/sup> expected to help expand access to semaglutide treatment options for adults with type 2 diabetes in Canada<\/em><\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Oakville, ON \u2014 July 21, 2026 <\/strong>\u2014 Aspen Pharmacare Canada Inc., a subsidiary of&nbsp; Aspen Pharmacare Holdings Limited (\u201cAspen\u201d), today announced that Health Canada has approved \u1d3e\u02b3Aspen-Semaglutide, a generic equivalent of Ozempic<sup>\u00ae<\/sup> (semaglutide injection), for the treatment of adults with type 2 diabetes mellitus to improve glycemic control, in combination with diet and exercise.\u00b9 Aspen-Semaglutide will offer both the 2 mg and 4 mg pen formats.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The approval marks an important milestone for Aspen Pharmacare Canada as it expands its portfolio of medicines available to patients in Canada.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>About Aspen-Semaglutide<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In Canada, Aspen-Semaglutide is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus to improve glycemic control, in combination with diet and exercise.\u00b9<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aspen-Semaglutide is approved in <strong>2 mg and 4 mg pre-filled pen formats<\/strong>, delivering:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>0.25 mg or 0.5 mg doses (2 mg \/ pen; 1.34 mg\/mL)<\/li>\n\n\n\n<li>1 mg doses (4 mg \/ pen; 1.34 mg\/mL)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Aspen is now advancing its launch plans to introduce this generic semaglutide to the Canadian market, working through established pharmaceutical wholesaler and pharmacy channels, healthcare practitioners and other stakeholders to reach patients across the country. The timing of commercialisation remains dependent on the availability of semaglutide active pharmaceutical ingredient supply. &#8220;Semaglutide is an important treatment option for many adults living with type 2 diabetes. We recognize the need for alternatives in this category and look forward to working with Canadian stakeholders to support availability following launch\u201d, said Mike Egli, General Manager of Aspen Pharmacare Canada.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Healthcare professionals should consult the complete Product Monograph <a href=\"https:\/\/aspenpharma.ca\/download\/3477\/?tmstv=1784647611\">here<\/a> for detailed information on indication, contraindications, warnings, precautions, adverse reactions, dosing, administration and patient monitoring requirements.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>About Aspen<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aspen Pharmacare Canada was founded in 2014 to offer the Aspen Group&#8217;s expanding portfolio of pharmaceutical and consumer healthcare products to Canadians. Aspen Pharmacare Canada is a subsidiary of Aspen Holdings Limited.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aspen is a South African-based global pharmaceutical company with a 170-year heritage and a presence in both emerging and developed markets. The Aspen Group supplies high-quality, affordable branded and generic medicines to patients in more than 115 countries and territories.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;The Group operates 24 manufacturing facilities across 15 sites \u2014 including sterile injectable capabilities \u2014 accredited by some of the most stringent regulatory agencies. Its manufacturing capabilities are scalable to demand and cover a wide variety of product types including steriles, oral solid dose, liquids, semi-solids, biologicals and active pharmaceutical ingredients. For more information visit <a href=\"http:\/\/www.aspenpharma.com\">www.aspenpharma.com<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Media and general inquiries<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For media, product or general inquiries, please contact Aspen Pharmacare Canada at <a href=\"mailto:hello@aspenpharma.ca\">hello@aspenpharma.ca<\/a>, and a member of our team will be pleased to assist.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ozempic<sup>\u00ae<\/sup> is a registered trademark of Novo Nordisk A\/S.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><sup>1<\/sup> Aspen-Semaglutide Product Monograph. Aspen Pharmacare Canada.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>New generic equivalent of Ozempic\u00ae expected to help expand access to semaglutide treatment options for adults with type 2 diabetes in Canada Oakville, ON \u2014 July 21, 2026 \u2014 Aspen Pharmacare Canada Inc., a subsidiary of&nbsp; Aspen Pharmacare Holdings Limited (\u201cAspen\u201d), today announced that Health Canada has approved \u1d3e\u02b3Aspen-Semaglutide, a generic equivalent of Ozempic\u00ae (semaglutide<\/p>\n","protected":false},"author":1,"featured_media":3509,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[41],"tags":[],"class_list":["post-3495","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-canadian-news"],"_links":{"self":[{"href":"https:\/\/aspenpharma.ca\/fr\/wp-json\/wp\/v2\/posts\/3495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aspenpharma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aspenpharma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aspenpharma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/aspenpharma.ca\/fr\/wp-json\/wp\/v2\/comments?post=3495"}],"version-history":[{"count":4,"href":"https:\/\/aspenpharma.ca\/fr\/wp-json\/wp\/v2\/posts\/3495\/revisions"}],"predecessor-version":[{"id":3507,"href":"https:\/\/aspenpharma.ca\/fr\/wp-json\/wp\/v2\/posts\/3495\/revisions\/3507"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aspenpharma.ca\/fr\/wp-json\/wp\/v2\/media\/3509"}],"wp:attachment":[{"href":"https:\/\/aspenpharma.ca\/fr\/wp-json\/wp\/v2\/media?parent=3495"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aspenpharma.ca\/fr\/wp-json\/wp\/v2\/categories?post=3495"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aspenpharma.ca\/fr\/wp-json\/wp\/v2\/tags?post=3495"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}